South Korea Medical Device Classification Explained: Class I, II, III, & IV

South Korea medical device classification is the foundation of every MFDS registration strategy. Before a medical device can be registered (notified, certified, and approved), imported, or marketed in Korea, it must first be assigned the correct classification under the Ministry of Food and Drug Safety (MFDS) framework.

From there, the South Korea medical device classification system defines all key regulatory requirements, including:

• The applicable registration pathway
• Technical documentation requirements
• Clinical evidence expectations
• Review timelines
• Ongoing compliance obligations

In this context, classification effectively sets the entire regulatory trajectory. Choosing the correct classification early can enable a streamlined market entry, while an incorrect classification may lead to delays, additional testing, and unexpected regulatory costs.

Continue below for a complete guide to South Korea medical device classification, or contact Cisema for support with MFDS medical device classification assessments, registration planning, and regulatory compliance.

What Is South Korea Medical Device Classification?

Like most major regulatory systems, South Korea uses a risk-based classification framework to determine the level of regulatory control applied to medical devices.

Devices are assigned to one of four risk classes according to factors such as intended use, method of operation, degree of invasiveness, duration of patient contact, anatomical location, energy source, and the potential consequences of device failure.

The four classes are:

• Class I (Low Risk)
• Class II (Moderate Risk)
• Class III (Higher Risk)
• Class IV (Highest Risk)

How Does MFDS Determine Medical Device Classification?

MFDS determines medical device risk classification based on its intended purpose and overall risk characteristics, considering factors such as:

• Intended use
• Principle of operation
• Degree of invasiveness
• Duration of contact with the human body
• Anatomical location
• Energy source
• Potential risks with device failure or malfunction
• Whether the device is intended to sustain or supports life

These factors are evaluated collectively, and the final classification is determined in accordance with the Korean Medical Device Act, related regulations, applicable MFDS product codes, and regulatory precedents

Korean classifications are ultimately determined within the MFDS framework and associated product-code system. As a result, manufacturers should not assume that a classification assigned by FDA or under EU MDR will automatically apply in Korea.

Even products that appear similar may be assigned different classifications if their intended use, clinical claims, or technological characteristics differ.

Understanding South Korea's Four Medical Device Risk Classes

While all medical devices are classified using the same risk-based framework, the regulatory expectations associated with each class differ significantly.

It is important to note, however, that medical device classification alone does not automatically determine whether clinical evidence is required. Under the MFDS regulatory framework, the need for clinical evidence, as well as the overall level of evidence required to demonstrate the safety and effectiveness of a medical device, is assessed on a case-by-case basis.

As a result, even certain Class I or Class II medical devices may require clinical evidence or additional supporting documentation, considering factors such as:

• Product Code
• Novelty of Technology
• Availability of Equivalent Devices
• Intended Use
• Applicable regulatory Precedent
• Level of evidence required to demonstrate the safety and effectiveness of the device

With these considerations in mind, the following sections examine each of South Korea's four medical device risk classes, outlining their characteristics, representative examples, and typical regulatory expectations.

Class I Medical Devices

Class I devices present minimal risk and are typically non-invasive, well-established products with limited patient interaction.

Examples include:

• Examination gloves
• Non-invasive surgical instruments
• Hospital furniture
• Basic medical accessories

These products benefit from a lighter regulatory burden, often including:

• Notification-based regulatory procedures with simplified documentation requirements
• Reduced technical review requirements
• Shorter approval timelines
• Lower compliance complexity

For Class I devices, regulatory oversight is generally handled through an MFDS notification-based process. Government fees are typically low, often ranging from several hundred to a few thousand US dollars depending on product scope and requirements.

Typical registration timelines often range from one to three months once all documentation has been prepared.

Although the regulatory burden is lighter, manufacturers must still comply with applicable Korean requirements relating to labelling, quality management, adverse event reporting, and post-market compliance.

Class II Medical Devices

Class II devices play a more active role in diagnosis, monitoring, or treatment and therefore require stronger evidence of safety and performance.

Examples include:

• Diagnostic ultrasound systems
• Infusion pumps
• Patient monitoring devices
• Certain dental devices
• Some diagnostic software products

Manufacturers may need to provide:

• Technical documentation
• Risk management files
• Performance testing data
• Product specifications
• Labeling information

Class II devices are reviewed either by MFDS or designated conformity assessment bodies, depending on applicable product code, category, characteristics and regulatory pathway.

Costs increase due to testing, translation, technical review, and quality system requirements, with total project budgets typically ranging from several thousand to tens of thousands of US dollars.

Review timelines generally range from 3–9 months, though software-based or testing-intensive products may take longer.

Many commonly used medical technologies fall within this category, making Class II one of the most frequently encountered classifications for overseas manufacturers entering Korea.

Class III Medical Devices

These products often perform critical medical functions, remain in the body for extended periods, or present more significant consequences if they malfunction.

Examples may include:

• Orthopedic implants
• Long-term invasive devices
• Certain surgical systems
• Advanced diagnostic technologies

At this level, the focus shifts from demonstrating basic safety and performance to providing comprehensive evidence that supports the device's overall benefit-risk profile.

Manufacturers are generally expected to submit:

• Comprehensive technical files
• Performance validation reports
• Biological safety evaluations
• Risk analyses
• Clinical evidence where required, including clinical data, equivalent device information, or other supporting evidence acceptable under applicable Korean regulation

Class III applications are typically reviewed directly by MFDS and undergo more detailed scientific and technical evaluation than lower-risk devices.

Costs are higher due to increased testing, documentation, and quality system requirements, often reaching tens of thousands of US dollars or more depending on complexity and clinical evidence needs.

Review timelines commonly range from 6–12 months, though additional clarification requests can extend this period.

At this level, documentation quality is critical: deficiencies frequently result in delays and additional MFDS queries.

Class IV Medical Devices

Class IV devices are life-sustaining or life-supporting technologies where failure could result in serious injury or death.

Examples may include:

• Implantable cardiac devices
• Heart valves
• Certain neurostimulation systems
• High-risk implantable technologies

Because device failure could result in serious injury or death, manufacturers must typically provide the most extensive body of technical, clinical, and quality-related evidence, including:

• Detailed technical documentation
• Comprehensive clinical evidence
• Long-term safety data
• Performance validation studies
• Manufacturing quality information
• Risk-benefit analyses

Class IV submissions are reviewed directly by MFDS and undergo intensive scientific and clinical evaluation.

Due to the depth of evidence required, costs can be substantial, often ranging from tens of thousands to well over one hundred thousand US dollars depending on clinical data needs, testing scope, and regulatory complexity.

Review timelines are typically the longest in the Korean system, commonly ranging from 9–18 months or longer, particularly for novel technologies and products requiring significant clinical evaluation.

Common Classification Challenges for Foreign Manufacturers

Many classification issues arise because manufacturers attempt to translate foreign approvals directly into the Korean regulatory framework.

Some of the most common classification issues involve products that do not fit neatly within established product categories or where Korean regulatory precedents differ from those in other jurisdictions.:

Software and AI-Based Medical Devices

Software classifications frequently depend on intended use, clinical functionality, level of automation, and risk associated with incorrect outputs.

Products classified under one category in another market may fall into a different Korean classification depending on applicable MFDS precedents.

Depending on the intended use and product functionality, certain software products may also fall within the scope of Korea's Digital Medical Products Act, which establishes a dedicated regulatory framework for digital medical products.

Novel Technologies

Innovative products may not fit clearly within existing Korean product codes or established regulatory categories.

In these situations, classification often requires detailed analysis of comparable technologies, risk characteristics, and previous MFDS decisions.

Combination Products

Products incorporating pharmaceutical, biologic, digital health, or medical device elements can present additional classification complexity, particularly where multiple regulatory frameworks overlap.

How to Determine the Correct MFDS Medical Device Classification

Correct classification is one of the most critical steps in the MFDS registration process. While some devices are straightforward, others — such as software-based medical devices, AI technologies, combination products, and novel technologies — require deeper analysis and careful interpretation of category-specific MFDS rules.

For these products, classification is rarely determined by risk alone. MFDS classifications are closely linked to Korean product codes, regulatory precedents, and device-specific intended uses. As a result, manufacturers should not assume that classifications assigned under FDA, EU MDR, or other regulatory frameworks will automatically apply in Korea.

A structured classification assessment typically involves:

1. Reviewing applicable Korean classification rules
2. Identifying relevant Korean product codes
3. Evaluating intended use and product claims
4. Identifying comparable MFDS-approved devices
5. Assessing device-specific risk factors
6. Confirming classification before submission planning

In practice, reviewing comparable MFDS-approved devices is often one of the most valuable steps in the process. Existing Korean approvals can provide important insight into how regulators are likely to classify similar products and what level of technical documentation, testing, or clinical evidence may ultimately be required.

Conducting a classification assessment early in product development or market-entry planning can significantly reduce regulatory uncertainty later in the process.

Key Takeaways for South Korea Medical Device Classification

Manufacturers can improve regulatory outcomes by approaching classification strategically.

1. Confirm Classification Early and Validate Against MFDS Precedents

Never assume a classification based solely on approvals obtained in other markets.

Korean classification rules and regulatory precedents are specific to the MFDS framework, making it important to review comparable MFDS-approved devices and validate classification before beginning registration activities.

2. Focus on Intended Use and Product Claims

Classification decisions are heavily influenced by a device's intended purpose, clinical application, and product claims.

Even minor changes to intended use statements can affect classification and regulatory requirements, making careful review essential before submission.

3. Align Evidence Requirements with Device Risk

Higher-risk devices require increasingly robust technical and clinical documentation.

As device risk increases, so do expectations for technical documentation, performance testing, risk management, and clinical evidence. Understanding the level of evidence required for the assigned classification helps avoid documentation gaps and review delays.

4. Build Regulatory Planning into Product Development

Classification should be considered as early as possible during product development and market-entry planning.

Early assessment can identify potential regulatory challenges, reduce the likelihood of costly redesigns, and support more realistic timelines and budgets.

5. Plan for Lifecycle Compliance, Not Just Initial Registration

Classification affects more than market approval.

It can influence quality management obligations, post-market surveillance requirements, change management activities, and ongoing compliance responsibilities throughout the product lifecycle. Taking a long-term view helps support smoother market access and regulatory maintenance in Korea.

Final Thoughts on South Korea Medical Device Classification

From determining the applicable approval pathway to defining documentation requirements, review expectations, and post-market obligations, medical device classification influences virtually every aspect of MFDS regulatory strategy.

Manufacturers that invest time in establishing the correct classification early are often better positioned to avoid delays, control costs, and bring products to market more efficiently. This is particularly important for innovative technologies, software-based devices, and products entering Korea for the first time.

Whether you are assessing a new product, planning market entry, or preparing an MFDS submission, Cisema provides regulatory expertise covering South Korea medical device classification, MFDS registration planning, regulatory strategy development, medical device registration, and ongoing post-market compliance activities across the Korean medical device market.

For tailored support with South Korea medical device classification and MFDS medical device registration, contact Cisema today.

About the Author: Will Noh

Will Noh brings more than 14 years of Regulatory Affairs and Quality Assurance experience across the medical device and healthcare industries, with deep expertise in South Korea’s Ministry of Food and Drug Safety (MFDS) regulatory framework. As Regulatory Affairs Manager at Cisema Korea, he supports international companies seeking market access in South Korea, providing regulatory, quality, and Local Authorized Representative (LAR) services for pharmaceuticals, medical devices, quasi-drugs, and cosmetics.

Further Information

Explore Cisema’s services for medical device registration in South Korea.

References

• Act on In-Vitro Diagnostic Medical Devices (체외진단의료기기법)
• Decree of The Act on In Vitro Diagnostic Medical Devices (체외진단의료기기법 시행령)
• Digital Medical Products Act (디지털의료제품법)
• Enforcement Decree Of The Digital Medical Products Act (디지털의료제품법 시행령)
• Enforcement Decree of the Medical Devices Act (의료기기법 시행령)
• Enforcement Rule of the Medical Devices Act (의료기기법 시행규칙)
• Medical Devices Act (의료기기법)
• MFDS Medical Devices Approval Process (의료기기 허가·인증·신고 절차)
• Regulation on Management of Safety Information Including Medical Device Adverse Events (의료기기 부작용 등 …

‍